These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 22883315)

  • 1. High-dose desvenlafaxine in outpatients with major depressive disorder.
    Ferguson JM; Tourian KA; Rosas GR
    CNS Spectr; 2012 Sep; 17(3):121-30. PubMed ID: 22883315
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies.
    Tourian KA; Padmanabhan SK; Groark J; Brisard C; Farrington D
    Clin Ther; 2009 Jun; 31 Pt 1():1405-23. PubMed ID: 19698901
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of desvenlafaxine 25 and 50▒mg/day in a randomized, placebo-controlled study of depressed outpatients.
    Iwata N; Tourian KA; Hwang E; Mele L; Vialet C
    J Psychiatr Pract; 2013 Jan; 19(1):5-14. PubMed ID: 23334675
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in the treatment of major depressive disorder.
    Septien-Velez L; Pitrosky B; Padmanabhan SK; Germain JM; Tourian KA
    Int Clin Psychopharmacol; 2007 Nov; 22(6):338-47. PubMed ID: 17917552
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Desvenlafaxine for the prevention of relapse in major depressive disorder: results of a randomized trial.
    Rickels K; Montgomery SA; Tourian KA; Guelfi JD; Pitrosky B; Padmanabhan SK; Germain JM; Leurent C; Brisard C
    J Clin Psychopharmacol; 2010 Feb; 30(1):18-24. PubMed ID: 20075643
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy, safety, and tolerability of fixed-dose desvenlafaxine 50 and 100 mg/day for major depressive disorder in a placebo-controlled trial.
    Boyer P; Montgomery S; Lepola U; Germain JM; Brisard C; Ganguly R; Padmanabhan SK; Tourian KA
    Int Clin Psychopharmacol; 2008 Sep; 23(5):243-53. PubMed ID: 18703933
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A 10-month, open-label evaluation of desvenlafaxine in Japanese outpatients with major depressive disorder.
    Tourian K; Wang Y; Ii Y
    Int Clin Psychopharmacol; 2013 Jul; 28(4):206-13. PubMed ID: 23587982
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Symptomatic and functional improvement in employed depressed patients: a double-blind clinical trial of desvenlafaxine versus placebo.
    Dunlop BW; Reddy S; Yang L; Lubaczewski S; Focht K; Guico-Pabia CJ
    J Clin Psychopharmacol; 2011 Oct; 31(5):569-76. PubMed ID: 21869698
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Short-term efficacy and safety of desvenlafaxine in a randomized, placebo-controlled study of perimenopausal and postmenopausal women with major depressive disorder.
    Kornstein SG; Jiang Q; Reddy S; Musgnung JJ; Guico-Pabia CJ
    J Clin Psychiatry; 2010 Aug; 71(8):1088-96. PubMed ID: 20797382
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of depressive symptoms in patients with major depressive disorder treated with desvenlafaxine or placebo.
    Kornstein SG; Fava M; Jiang Q; Tourian KA
    Psychopharmacol Bull; 2009; 42(3):21-35. PubMed ID: 19752839
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Duloxetine for the treatment of major depressive disorder: safety and tolerability associated with dose escalation.
    Wohlreich MM; Mallinckrodt CH; Prakash A; Watkin JG; Carter WP
    Depress Anxiety; 2007; 24(1):41-52. PubMed ID: 16845641
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BDNF, interleukin-6, and salivary cortisol levels in depressed patients treated with desvenlafaxine.
    Ninan PT; Shelton RC; Bao W; Guico-Pabia CJ
    Prog Neuropsychopharmacol Biol Psychiatry; 2014 Jan; 48():86-91. PubMed ID: 24096053
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in adult outpatients with major depressive disorder.
    Liebowitz MR; Yeung PP; Entsuah R
    J Clin Psychiatry; 2007 Nov; 68(11):1663-72. PubMed ID: 18052559
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy, safety, and tolerability of desvenlafaxine 50 mg/day and 100 mg/day in outpatients with major depressive disorder.
    Liebowitz MR; Manley AL; Padmanabhan SK; Ganguly R; Tummala R; Tourian KA
    Curr Med Res Opin; 2008 Jul; 24(7):1877-90. PubMed ID: 18507895
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A double-blind, placebo-controlled study of the efficacy and safety of desvenlafaxine succinate in the treatment of major depressive disorder.
    DeMartinis NA; Yeung PP; Entsuah R; Manley AL
    J Clin Psychiatry; 2007 May; 68(5):677-88. PubMed ID: 17503976
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized, double-blind comparison of duloxetine and venlafaxine in the treatment of patients with major depressive disorder.
    Perahia DG; Pritchett YL; Kajdasz DK; Bauer M; Jain R; Russell JM; Walker DJ; Spencer KA; Froud DM; Raskin J; Thase ME
    J Psychiatr Res; 2008 Jan; 42(1):22-34. PubMed ID: 17445831
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A double-blind, randomized, placebo-controlled study assessing the efficacy and tolerability of desvenlafaxine 10 and 50 mg/day in adult outpatients with major depressive disorder.
    Liebowitz MR; Tourian KA; Hwang E; Mele L;
    BMC Psychiatry; 2013 Mar; 13():94. PubMed ID: 23517291
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of desvenlafaxine 50 mg compared with placebo in patients with moderate or severe major depressive disorder: a pooled analysis of six randomized, double-blind, placebo-controlled studies.
    Papakostas GI; Culpepper L; Fayyad RS; Musgnung J; Guico-Pabia CJ
    Int Clin Psychopharmacol; 2013 Nov; 28(6):312-21. PubMed ID: 23881185
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A placebo-controlled study evaluating the efficacy and safety of flexible-dose desvenlafaxine treatment in outpatients with major depressive disorder.
    Feiger AD; Tourian KA; Rosas GR; Padmanabhan SK
    CNS Spectr; 2009 Jan; 14(1):41-50. PubMed ID: 19169187
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discontinuation symptoms and taper/poststudy-emergent adverse events with desvenlafaxine treatment for major depressive disorder.
    Montgomery SA; Fava M; Padmanabhan SK; Guico-Pabia CJ; Tourian KA
    Int Clin Psychopharmacol; 2009 Nov; 24(6):296-305. PubMed ID: 19779354
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.